Divi's Laboratories Limited vs Neuland Laboratories Limited
An objective side-by-side of DIVISLAB and NEULANDLAB, both in Pharmaceuticals - Indian - Bulk Drugs: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: DIVISLAB Jun 2026 · NEULANDLAB Mar 2026
At a glance
- Divi's Laboratories Limited is the larger company by market value, about 8.6 times the size of Neuland Laboratories Limited.
- On trailing earnings, Neuland Laboratories Limited trades at the lower P/E (79.7 against 85.4).
- Neuland Laboratories Limited earns the higher return on equity (19.4% against 17.5%).
- Over three years Neuland Laboratories Limited has grown profits faster (30% a year against 13%).
- Over the past year the share prices returned +55.4% (DIVISLAB) and +44.3% (NEULANDLAB).
| Metric | Divi's Laboratories DIVISLAB |
Neuland Laboratories NEULANDLAB |
|---|---|---|
| Size and price | ||
| Market cap | ₹249,819 Cr | ₹29,008 Cr |
| Share price | ₹9,410 | ₹22,610 |
| Valuation | ||
| P/E | 85.41 | 79.66 |
| P/B | 14.90 | 15.47 |
| EV/EBITDA | 62.98 | 51.07 |
| PEG | 6.57 | 2.66 |
| Dividend yield | 0.3% | 0.2% |
| Profitability | ||
| ROE | 17.5% | 19.4% |
| ROCE | 22.0% | 27.0% |
| Operating margin | 35.3% | 28.4% |
| Sales (TTM) | ₹11,230 Cr | ₹2,023 Cr |
| Net profit (TTM) | ₹2,925 Cr | ₹364 Cr |
| Growth | ||
| Latest quarter sales YoY | +27.8% | +136.3% |
| Latest quarter profit YoY | +65.5% | +666.0% |
| Sales CAGR 3Y | +11.0% | +19.0% |
| Profit CAGR 3Y | +13.0% | +30.0% |
| Sales CAGR 5Y | +9.0% | +17.0% |
| Profit CAGR 5Y | +6.0% | +39.0% |
| Financial strength | ||
| Debt/Equity | 0.00 | 0.16 |
| Interest cover | 129.48 | 20.31 |
| Ownership | ||
| Promoter holding | 51.9% | 32.6% |
| Promoter change (4 qtrs) | +0.00 pp | -0.05 pp |
| Price performance | ||
| Return 1M | +9.81% | -4.06% |
| Return 3M | +38.64% | +31.27% |
| Return 1Y | +55.37% | +44.27% |
| Return YTD | +47.21% | +49.00% |
| Technical condition | ||
| Technical score | 73 | 48 |
| RS rating (1-99) | 90.00 | 90.00 |
| % vs 200-DMA | +36.05% | +34.84% |
| RSI (14) | 63.85 | 49.70 |
| % from 52-week high | -2.13% | -6.67% |
